Today's Daily Dose brings you news about clinical hold on Affimed's AFM11 phase I program; Altimmune's $25 million registered direct offering; FDA approval of Bausch Health's BRYHALI Lotion; Menlo's disappointing phase II trial results of Serlopitant and Recro Pharma's anticipated make or break event.
from RTT - Biotech https://ift.tt/2IIjaq5
via IFTTT
No comments:
Post a Comment